ICO THERAPEUTICS
ICo Therapeutics is focused on the research and development of drug delivery technologies. By focusing efforts on development instead of research, iCo's business model aims to acquire the rights to drugs that are either off-patent, currently approved, or near commercialization and develop them by redosing or reformulating them for new or expanded labels. The subsequent development of these therapeutics may include drug delivery technologies-such as sustained-release or biodegradable matrices to extend patent coverage.
ICO THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2005-01-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.icotherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
604.602.9414
Email Addresses:
[email protected]
Total Funding:
8.58 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS GoDaddy DNS Gravatar Profiles GoDaddy WPForms
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-03-22 | Satellos Bioscience | Satellos Bioscience acquired by iCo Therapeutics | N/A |
Investors List
National Research Council of Canada Industrial Research Assistance Program
National Research Council of Canada Industrial Research Assistance Program investment in Grant - iCo Therapeutics
Official Site Inspections
http://www.icotherapeutics.com
- Host name: 195-154-48-61.rev.poneytelecom.eu
- IP address: 195.154.48.61
- Location: Avon France
- Latitude: 48.4022
- Longitude: 2.7202
- Timezone: Europe/Paris
- Postal: 77210
More informations about "iCo Therapeutics"
Corporate Overview - iCo Therapeutics
ICo Therapeutics is an emerging Vancouver-based biotechnology company committed to developing drugs for a range of human medical conditions within isolated biological …See details»
About - iCo Therapeutics
iCo Therapeutics Company Profile | Management and Employees …
Www.icotherapeutics.com . Contact Information. Headquarters. 777 Hornby St Fl 6, Vancouver, British Columbia, V6Z 2T3, Canada (778) 802-9806. iCo Therapeutics Profile and History . iCo …See details»
Satellos Bioscience - Crunchbase Company Profile & Funding
Organization. Satellos Bioscience . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; …See details»
iCo Therapeutics receives funding from the Government of
May 31, 2012 For more information, visit the Company website at: www.icotherapeutics.com. ... Organization Profile. iCo Therapeutics Inc. Contact Cision. 866-245-2317 from 8 AM - 10 PM ETSee details»
iCo Therapeutics Inc. Announces Shareholder Approval of Business ...
Aug 5, 2021 iCo is a Canadian biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat ocular and infectious diseases.See details»
ICO Therapeutics Company Profile 2024: Valuation, Investors ...
ICO Therapeutics General Information Description. iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic …See details»
iCo Therapeutics Inc. - Vancouver, Canada - bionity.com
ICo Therapeutics Inc. is a Vancouver-based development based company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has …See details»
iCo Therapeutics, Inc. Announces Agreement for in Vivo Testing of …
Mar 16, 2021 Vancouver, British Columbia--(Newsfile Corp. - March 15, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announced that its …See details»
iCo Therapeutics - Products, Competitors, Financials, Employees ...
ICo Therapeutics (ICO: TSX-V, ICOTF:OTCQX) is a biotechnology company that specializes in the development of existing drugs by repositioning, redosing, and reformulating them for new …See details»
iCo Therapeutics Inc. Announces TSX Venture Exchange …
Jul 9, 2021 iCo is a Canadian biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat ocular and infectious diseases.See details»
Investor Relations - iCo Therapeutics
ICo Investor Relations. Please visit the TSX site for up to date trading information.. Fact Sheets. Corporate fact sheet ICO_fact_sheet.pdf iCo-007 iCo-007_fact_sheet.pdf iCo-008 iCo …See details»
iCo Therapeutics Inc. Announces Shareholder Approval of Business ...
Aug 5, 2021 Vancouver, BC –(Newsfile Corp.) – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or the “Company”) is pleased to announce that at an annual and special …See details»
Overview - iCo Therapeutics
May 21, 2006 iCo Therapeutics is committed to developing or modifying existing drugs for a range of conditions within ‘isolated biological environments’, such as the eye, spinal cord or …See details»
iCo Therapeutics Announces Joint Development of iCo-019 with
Dec 31, 2020 iCo Therapeutics, iCo Therapeutics, Inc. and Skymount Medical, Inc. announced today that they have entered into a non-binding Memorandum of Understanding to develop …See details»
iCo Therapeutics Inc. Agrees to a Business Combination with …
Mar 22, 2021 Vancouver, British Columbia--(Newsfile Corp. - March 22, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo") and Satellos Bioscience Inc. …See details»
iCo Investor Information: News - iCo Therapeutics
Dec 31, 2020 Title Date; iCo Therapeutics Inc.: Carc – Online Pharmacy Services and Canadian Drugs: July 18, 2024: iCo Therapeutics, Inc. announces agreement for in vivo testing of iCo- …See details»
iCo Therapeutics Announces Joint Development of iCo-019 with …
Dec 31, 2020 For more information, visit the Company website at: www.icotherapeutics.com. No regulatory authority has approved or disapproved the content of this press release. Neither the …See details»
iCo Therapeutics Announces Oral Amphotericin B (iCo-019) …
Apr 22, 2022 June 22, 2020, Vancouver, Canada – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or “the Company”) and its subsidiary, iCo Therapeutics Australia Pty Ltd., …See details»